CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSPNYSE / NASDAQHealthcareSmall cap

$39.10+$0.17 (+0.4%)

Last close · Data as of Nov 20, 2026

Market cap
$5.5B
Revenue
$0.00
ROCE
-34.6%

-20.7% over the last year

CRISPR Therapeutics AG price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-21.6%
3M
-32.7%
6M
-19.5%
1Y
-20.7%
5Y
-52.6%

52-week range

Day change +$0.17 (+0.4%) from $39 to $39 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CRSP, bought on each weekday since 2021.

News & filings

What CRISPR Therapeutics AG filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 582 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.

Read moreShow less

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Sector
Healthcare
Shares outstanding
95.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.5B
P/B
2.9x
52-week high
$61.89
52-week low
$38.93

Profitability

ROE
-30.3%
ROCE
-34.6%
ROIC
-29.5%
ROA
-25.7%

Growth

Revenue
$0.00
Revenue growth, 1Y
-100.0%
Net profit growth, 1Y
58.8%
Free cash flow
-$370.9M

Solvency

Current ratio
13.32
Debt / Equity
0.11
Debt / Assets
0.09
CFO / Net profit
0.59
Cash / Market cap
36.0%

Revenue and net profit

Revenue fell 100.0% in FY2025; net profit is the dashed line.

CRISPR Therapeutics AG revenue and net profit by fiscal year
CRISPR Therapeutics AG revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$436.0k-$650.2M
FY2023$370.0M-$153.6M
FY2024$35.0M-$366.3M
FY2025$0.00-$581.6M

Cash flows

FY2025: -$345.0M from operations, -$370.9M free after investment (dashed).

CRISPR Therapeutics AG operating and free cash flow by fiscal year
CRISPR Therapeutics AG operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$495.7M-$532.9M
FY2023-$260.4M-$272.3M
FY2024-$142.8M-$144.7M
FY2025-$345.0M-$370.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00-100.0%1Y
EBITDA
-$645.1M
Net profit
-$581.6M
Cash from operations
-$345.0M
Free cash flow
-$370.9M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$645.1M-$581.6M-$370.9M-30.3%-100.0%+58.8%

Monthly returns

Month-by-month returns of CRSP across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.3B
Liabilities$343.4M
Equity$1.9B
Paid-in capital$3.9B
Retained earnings-$1.9B
Treasury stock$60.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CRSP highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): CRISPR Therapeutics AG, Cogent Biosciences, Inc., Scholar Rock Holding Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
CRISPR Therapeutics AGCRSPthis company$5.5B—2.9x-30.3%—
Rhythm Pharmaceuticals, Inc.RYTM$6.0B—22.3x-74.8%—
PACS Group, Inc.PACS$5.9B31.0x6.3x20.2%25.0x
Mirum Pharmaceuticals, Inc.MIRM$5.6B-241.4x17.9x-7.4%329.1x
Cogent Biosciences, Inc.COGT$5.6B-17.0x10.2x-60.1%-17.2x
Liquidia CorporationLQDA$5.6B-80.7x124.3x-154.0%-128.8x
Scholar Rock Holding CorporationSRRK$5.4B—22.1x-154.0%—
Xenon Pharmaceuticals Inc.XENE$5.1B-14.8x8.8x-59.5%-13.3x
CG Oncology, Inc.CGON$4.9B-30.7x6.6x-21.4%-26.0x
Peer median—-23.9x14.1x-59.8%-15.3x

Year-to-date ROI

CRSP since 1 January, against earlier years.

Historical volatility

CRSP's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

CRISPR Therapeutics AG operating margin by fiscal year
CRISPR Therapeutics AG operating margin by fiscal year
DateOperating margin
FY2022-152990.9%
FY2023-60.1%
FY2024-1333.1%
FY2025—
LineFY2025
Cost of revenueCost Of Revenue$213.5M
Gross profitGross Profit-$213.5M
Operating expensesOperating Expense$451.1M
Research and developmentResearch And Development$381.1M
Other operating expensesOther Operating Expenses-$3.5M
Total expensesTotal Expenses$664.6M
Pretax incomePretax Income-$578.0M

Learn while you research

Academy chapters picked for CRISPR Therapeutics AG and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →